Relapsed or Refractory High-Risk Myelodysplastic Syndrome, Relapsed / Refractory Metastatic or Advanced Solid Tumors, Acute Myeloid Leukemia with or without NPM1 Mutation
Conditions
Brief summary
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Detailed description
Time from the first administration of RVU120-based treatment in the parent study until discontinuation of RVU120-based treatment for any reason in the rollover study
Interventions
Sponsors
Ryvu Therapeutics S.A.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) | — |
Secondary
| Measure | Time frame |
|---|---|
| Time from the first administration of RVU120-based treatment in the parent study until discontinuation of RVU120-based treatment for any reason in the rollover study | — |
Countries
France, Italy, Poland, Spain
Outcome results
None listed